Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 5Phase 1/2 3Phase 1 3

Status

Completed 5Terminated 3Unknown 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × ibritumomab tiuxetan × Clear all
NCT00372905 2019-09-04

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Northwestern University

Phase 1/2 Terminated
18 enrolled 10 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00089284 2019-08-14

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Northwestern University

Phase 1/2 Terminated
30 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡